Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes

Completed · Not applicable

Conditions studied: End Stage Kidney Disease

In brief

Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.

Key facts

Study ID

NCT05741489

Run by

Emory University

People needed

40

Starts

2022-08-10

Expected to finish

2023-03-09

Last updated by the study team

2024-04-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dialysis treatment for more than 3 months
• HbA1c less than 6.5% at the first clinic visit
• Willing to wear a CGM for 10 days

You may not qualify if…

• Have used insulin or any diabetes treatment during the last 3 months
• Be pregnant or plan to become pregnant during the study
• Known allergy to medical-grade adhesives
• Taking acetaminophen (more than 1 gram every six hours) or hydroxyurea (may interfere with sensor membrane)
• Current or anticipated use of stress steroid doses (prednisone </= 5 mg or its equivalent is allowed)

Where it is running

• Grady Memorial Hospital — Atlanta, Georgia, United States
• Emory Dialysis at Northside — Atlanta, Georgia, United States
• Emory Dialysis at Greenbriar — Atlanta, Georgia, United States
• Emory Dialysis at Candler — Decatur, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.